Calithera Biosciences Inc. (CALA)
Symbol Info
Listed Symbol CALA
Name Calithera Biosciences Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $22,254,000
Latest Fiscal EPS $-1.49
Price Info
21 Day Moving Average $4.0200
21 Day EMA $4.018660
50 Day Moving Average $4.2813
50 Day EMA $4.357200
200 Day EMA $5.186350
200 Day Moving Average 5.082700
52 Week High $6.90
52 Week Low $3.43
52 Week Change $-14.680900
Alpha 0.001604
Beta 1.8496
Standard Deviation 0.269425
R2 0.058090
Periods 58
Share Information
10 Day Average Volume 305,630
20 Day Average Volume 291,548
30 Day Average Volume 317,613
50 Day Average Volume 510,545
Outstanding Shares 53,774,902
Float Shares 53,560,775
Percent Float 99.60%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 183
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 3,558,472
Institute Holdings Percent 79.600000
Institute Sold Previous 3 Months 2,449,016
Insider Holdings Date 2019-07-31
Insider Bought Previous 3 Months 12
Insider Holdings Percent 0.50%
Insider Sold Previous 3 Months 416
Insiders Shares Owned 214,127
Price Change
7 Day Price Change $0.3900003
7 Day Percent Change 10.77%
21 Day Price Change $-0.1499996
21 Day Percent Change -3.61%
30 Day Price Change $-0.3499999
30 Day Percent Change -8.03%
Month To Date Price Change $-0.23
Month To Date Percent -5.42%
90 Day Price Change $-1.71
90 Day Percent Change -29.90%
Quarter To Date $0.110000
Quarter To Date Percent 2.82%
180 Day Price Change $-1.35
180 Day Percent Change -25.19%
200 Day Price Change $-0.07
200 Day Percent Change -1.72%
Year To Date $-
Year To Date Percent -
Profile
Description Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm is functioned through the region of US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its lead product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.
Details
Issue Type CS
Market Cap $215,637,357
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 53,774,902
CEO Susan M. Molineaux
Employees 79
Last Audit UE
Classification
CIK 0001496671
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 343 Oyster Point Boulevard
Suite 200
South San Francisco, CA 94080
Website https://www.calithera.com
Facisimile +1 650 588-5272
Telephone +1 650 870-1000
Email ir@calithera.com
Key Ratios
Profitability
EBIT Margin -397.7
EBITDA Margin -394.8
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $65,462,117
Price To Sales -
Price To Free Cash -2.9
PE High Last 5 Years -
Price To Book 1.5
Price To Cash Flow 14.7
PE Low Last 5 Years -
Price To Tangible Book 1.5
Financial Strength
Total Debt To Equity 0.1
Int Coverage -
Current Ratio 8.1
Leverage Ratio 1.2
Quick Ratio 8.0
Long Term Debt To Capital 0.05
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -52.98
Return On Equity -60.16
Return On Capital -56.62
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
CALA
Calithera ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.